1: Hogg PJ. Toxicokinetics of the tumour cell mitochondrial toxin, PENAO, in rodents. Invest New Drugs. 2021 Jun;39(3):756-763. doi: 10.1007/s10637-021-01065-x. Epub 2021 Jan 19. PMID: 33469723.
2: Shen H, Decollogne S, Dilda PJ, Hau E, Chung SA, Luk PP, Hogg PJ, McDonald KL. Dual-targeting of aberrant glucose metabolism in glioblastoma. J Exp Clin Cancer Res. 2015 Feb 5;34(1):14. doi: 10.1186/s13046-015-0130-0. PMID: 25652202; PMCID: PMC4324653.
3: Decollogne S, Joshi S, Chung SA, Luk PP, Yeo RX, Nixdorf S, Fedier A, Heinzelmann-Schwarz V, Hogg PJ, Dilda PJ. Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells. Gynecol Oncol. 2015 Aug;138(2):363-71. doi: 10.1016/j.ygyno.2015.06.018. Epub 2015 Jun 14. PMID: 26080289.
4: Sarkar S, Tran B, Horvath L, Lam M, Savas P, Grimison P, Whittle JR, Kuo JC, Signal N, Edmonds D, Hogg P, Rischin D, Desai J, Hamilton A. A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2021 May;87(5):613-620. doi: 10.1007/s00280-020-04225-7. Epub 2021 Jan 26. PMID: 33496801.
5: Wang X, Yeo RX, Hogg PJ, Goldstein D, Crowe P, Dilda PJ, Yang JL. The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. Oncotarget. 2020 Jan 7;11(1):46-61. doi: 10.18632/oncotarget.27416. PMID: 32002123; PMCID: PMC6967775.
6: Seneviratne JA, Carter DR, Mittra R, Gifford A, Kim PY, Luo JS, Mayoh C, Salib A, Rahmanto AS, Murray J, Cheng NC, Nagy Z, Wang Q, Kleynhans A, Tan O, Sutton SK, Xue C, Chung SA, Zhang Y, Sun C, Zhang L, Haber M, Norris MD, Fletcher JI, Liu T, Dilda PJ, Hogg PJ, Cheung BB, Marshall GM. Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. Int J Cancer. 2023 Apr 1;152(7):1399-1413. doi: 10.1002/ijc.34349. Epub 2022 Nov 17. PMID: 36346110; PMCID: PMC10953412.
7: Gang BP, Dilda PJ, Hogg PJ, Blackburn AC. Targeting of two aspects of metabolism in breast cancer treatment. Cancer Biol Ther. 2014;15(11):1533-41. doi: 10.4161/15384047.2014.955992. PMID: 25482950; PMCID: PMC4622508.
8: Noy JM, Chen F, Akhter DT, Houston ZH, Fletcher NL, Thurecht KJ, Stenzel MH. Direct Comparison of Poly(ethylene glycol) and Phosphorylcholine Drug-Loaded Nanoparticles In Vitro and In Vivo. Biomacromolecules. 2020 Jun 8;21(6):2320-2333. doi: 10.1021/acs.biomac.0c00257. Epub 2020 May 12. PMID: 32343128.
9: Peña-Otero D. COVID-19 Vaccination. Where Are We and Where Should We Go? Arch Bronconeumol. 2022 Apr;58 Suppl 1:11-12. doi: 10.1016/j.arbres.2022.03.009. Epub 2022 Apr 15. PMID: 35489982; PMCID: PMC9012507.
10: Noy JM, Lu H, Hogg PJ, Yang JL, Stenzel M. Direct Polymerization of the Arsenic Drug PENAO to Obtain Nanoparticles with High Thiol-Reactivity and Anti- Cancer Efficiency. Bioconjug Chem. 2018 Feb 21;29(2):546-558. doi: 10.1021/acs.bioconjchem.8b00032. Epub 2018 Feb 7. PMID: 29346731.
11: Park D, Chiu J, Perrone GG, Dilda PJ, Hogg PJ. The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase. Cancer Cell Int. 2012 Mar 26;12(1):11. doi: 10.1186/1475-2867-12-11. PMID: 22448968; PMCID: PMC3349534.
12: Noy JM, Chen F, Stenzel M. Post-functionalization of drug-loaded nanoparticles prepared by polymerization-induced self-assembly (PISA) with mitochondria targeting ligands. Beilstein J Org Chem. 2021 Sep 3;17:2302-2314. doi: 10.3762/bjoc.17.148. PMID: 34621393; PMCID: PMC8450966.
13: Tsoli M, Liu J, Franshaw L, Shen H, Cheng C, Jung M, Joshi S, Ehteda A, Khan A, Montero-Carcabosso A, Dilda PJ, Hogg P, Ziegler DS. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. Oncotarget. 2018 Jan 8;9(7):7541-7556. doi: 10.18632/oncotarget.24045. PMID: 29484131; PMCID: PMC5800923.
14: Noy JM, Cao C, Stenzel M. Length of the Stabilizing Zwitterionic Poly(2-methacryloyloxyethyl phosphorycholine) Block Influences the Activity of the Conjugated Arsenic Drug in Drug-Directed Polymerization-Induced Self- Assembly Particles. ACS Macro Lett. 2019 Jan 15;8(1):57-63. doi: 10.1021/acsmacrolett.8b00853. Epub 2018 Dec 21. PMID: 35619410.
15: Dilda PJ, Decollogne S, Weerakoon L, Norris MD, Haber M, Allen JD, Hogg PJ. Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J Med Chem. 2009 Oct 22;52(20):6209-16. doi: 10.1021/jm9008339. PMID: 19788237.